Nabla CAIHL draft report

HugoScore CAIHL Draft Report: Nabla

Status: Draft for human review Generated: 2026-06-08 Last reviewed: 2026-06-08 Review method: Deep public-source review of official product pages, trust/security pages, consent guidance, privacy policy, customer/public evidence, and published ambient-scribe research; no vendor interview or hands-on deployment testing. Service: Nabla Vendor: Nabla Technologies Category: Ambient scribe / AI clinical assistant

Executive Summary

Nabla is an AI clinical assistant for ambient documentation, EHR-integrated note generation, multilingual support, coding/order workflows, and clinician documentation relief.

From a CAIHL perspective, Nabla is institution-led and clinician-mediated. Its public materials are comparatively strong on some governance points: patient-consent language, no audio storage by default, no AI training on clinical notes, and configurable note retention. But actual notice, refusal, access, and correction rights remain deployment-specific.

Agency posture: Mixed Confidence: Medium draft

Evidence

• Nabla homepage: https://www.nabla.com/
• Nabla product page: https://www.nabla.com/product
• Nabla patient consent page: https://www.nabla.com/ask-patient-consent
• Nabla Trust Center: https://trust.nabla.com/
• Nabla Privacy Policy: https://www.nabla.com/legal/privacy-policy
• The Permanente Medical Group/Nabla ambient AI scribe study: https://www.nejm.org/doi/full/10.1056/CAT.24.0134
• Randomized trial abstract: https://pubmed.ncbi.nlm.nih.gov/41239327/

Mixed HugoScore Profile

• Who does this AI serve? Institutional / clinician-mediated. Nabla is sold to clinicians and healthcare organizations for documentation and workflow support.
• Can patients tell AI is involved? Partial to yes. Nabla publishes consent language, but actual notice depends on deployment.
• Can patients meaningfully choose? Partial. Consent is described, but opt-out/refusal workflow and alternatives depend on the health system.
• Can patients correct or challenge what the AI produces? Partial. Clinician review is central, but patient transcript/audio access and AI-specific correction routes are not clearly established.
• Does it help patients understand or act? Indirectly. It may improve clinician attention and notes, but it is not a patient-controlled advocacy or navigation tool.

Patient Agency Interpretation

Nabla's no-audio-by-default and no-training-on-clinical-notes claims are meaningful positives for CAIHL review. Still, the patient usually experiences the tool through the clinician and health system. Without patient access, correction, and refusal rights, the tool may improve workflow without increasing patient control over the record.

Publication Recommendation

Ready for human review as a draft profile. Do not publish as final until deployment-specific consent, refusal, transcript/audio access, correction, retention, model-provider, and equity-performance details are verified.